Eton Pharmaceuticals, Inc.
ETONHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. At a $1.43B market cap, Eton Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Market Cap
$1.43B
Beta
0.90
P/E (TTM)
125.00
P/E (Fwd)
19.61
EPS (TTM)
$0.40
EPS (Fwd)
$2.55
ROE
36.0%
ROA
11.9%
Cash
$26.8M
Total Debt
$29.2M
Free CF
$6.6M
52W Change
170.6%
Annual Financials
Cash vs Debt
Where ETON stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ETON finished 22.93% above its 150-day moving average ($40.04) and 44.17% above its 200-day moving average ($34.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ETON overbought or oversold?
At the October 20, 2026 close, ETON's RSI(14) was 24.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $26.8M in cash, though total debt stands at $29.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $6.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 36.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has grown from $21.3M (2022) to $80.0M (2025), reflecting a 276% increase over the period.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eton Pharmaceuticals, Inc. and its sector.